Back to results
US 2026/0130949 A1Published application
Pancreatic cells for treating diabetes and methods of generating the same
AssigneeSeraxis, Inc.
InventorWilliam L. Rust
Life of this patent
Estimating the term…
Abstract
The present disclosure provides cell-based compositions for treating diabetes, methods for identifying cells that preferentially differentiate into endoderm cells, and methods for preparing insulin-producing pancreatic cells, as well as related methods of use for treating diseases related to insulin deficiency.
Claims19
-4. (canceled)
A method of producing insulin-secreting cells, comprising:
- (a) culturing human stem cells on an adhesive substrate in a first medium comprising Activin-A and Wortmannin, wherein the human stem cells are not exposed to Wnt3a, wherein the human stem cells are capable of differentiating into at least endodermal lineages;
- (b) further culturing the human stem cells in at least one additional medium comprising retinoic acid and cyclopamine;
- and
- (c) transferring the human stem cells to a suspension culture when the cells form three-dimensional cell structures;
- wherein the cells are exposed to retinoic acid and cyclopamine for at least 20 days.
2 more elements
-41. (Canceled)
A method of producing insulin-secreting cells, comprising
- (a) culturing human stem cells in a first medium comprising Activin-A and Wortmannin, thereby differentiating the human stem cells into endoderm cells, wherein the human stem cells were not exposed to keratinocyte growth factors (KGF) prior to differentiation into endoderm cells;
- and
- (b) culturing the endoderm cells from (a) in a second medium comprising retinoic acid and cyclopamine, thereby differentiating the endoderm cells into endocrine cells;
- (c) culturing the endocrine cells from (b) in a third medium comprising KGF, noggin, and EGF, thereby differentiating the endocrine cells into pancreatic progenitor cells;
- (d) culturing the pancreatic progenitor cells from (c) in a fourth medium comprising noggin, EGF, γ-secretase inhibitor XXI, and Alk5i II, thereby differentiating the pancreatic progenitor cells into insulin-producing cells.
2 more elements
-71. (canceled)
A cell culture system comprising:
- (a) human stem cells selected from the group consisting of embryonic stem cells, induced pluripotent stem cells, and multipotent reprogrammed stem cells, wherein the human stem cells are capable of differentiating into at least endodermal lineages, and wherein the human stem cells spontaneously form three-dimensional structures and are in suspension in the cell culture system;
- (b) retinoic acid;
- and
- (c) cyclopamine,
- wherein the cell culture system does not comprise Wnt3A.
2 more elements
Dependencies are inferred from the claim text.